Sorkin John D, Vasaitis Tadas Sean, Streeten Elizabeth, Ryan Alice S, Goldberg Andrew P
Divisions of Gerontology and Geriatric Medicine and.
J Nutr. 2014 May;144(5):734-42. doi: 10.3945/jn.114.190660. Epub 2014 Apr 9.
We identified normal vs. abnormal 25-hydroxyvitamin D [25(OH)D] concentrations by examining the relation of 25(OH)D to non-bone-related measures (plasma glucose, insulin resistance, lipids, blood pressure, fitness, obesity, and regional adiposity) and asking whether there is a 25(OH)D concentration above and below which the relation between 25(OH)D and outcome changes. We examined the relation between 25(OH)D and outcome by race to see whether race-specific normal ranges are needed, and we examined the role of insulin-like growth factor-1 (IGF-1) in modulating the relation between 25(OH)D and outcome. In a cross-sectional study of 239 overweight and obese, sedentary postmenopausal women without diabetes (83 black, 156 white), outcome measures included plasma lipids, glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), IGF-1, parathyroid hormone (PTH), aerobic fitness, body composition, subcutaneous abdominal and visceral fat, and blood pressure. We identified threshold effects in the association between 25(OH)D and these variables using piecewise linear regressions. We found that 25(OH)D was inversely related to fasting glucose, fasting and 2-h insulin, HOMA-IR, visceral abdominal fat, percentage fat, PTH, and triglycerides. Evidence for a threshold effect of 25(OH)D was found for 2-h glucose, 2-h insulin, fasting insulin, and HOMA-IR. There was no evidence suggesting the need for race-specific normal 25(OH)D concentrations. IGF-1 modulated the relation between 25(OH)D and outcome but only below, and not above, a threshold 25(OH)D concentration. Our findings suggest a threshold effect of 25(OH)D on glucose-insulin metabolism such that 25(OH)D ≥ ∼26 μg/L (65.0 pmol/L) supports normal glucose homeostasis and that the same cut point defining normal 25(OH)D concentration can be used in black and white women. This study was registered at clinicaltrials.gov as NCT01798030.
我们通过研究25-羟基维生素D[25(OH)D]与非骨骼相关指标(血浆葡萄糖、胰岛素抵抗、血脂、血压、体能、肥胖及局部脂肪量)之间的关系,并询问是否存在一个25(OH)D浓度界限,高于或低于此界限时25(OH)D与结局之间的关系会发生变化,从而确定正常与异常的25(OH)D浓度。我们按种族研究了25(OH)D与结局之间的关系,以查看是否需要种族特异性的正常范围,并且我们研究了胰岛素样生长因子-1(IGF-1)在调节25(OH)D与结局之间关系中的作用。在一项针对239名超重和肥胖、久坐不动且无糖尿病的绝经后女性(83名黑人,156名白人)的横断面研究中,结局指标包括血脂、葡萄糖、胰岛素、胰岛素抵抗的稳态模型评估(HOMA-IR)、IGF-1、甲状旁腺激素(PTH)、有氧体能、身体成分、腹部皮下及内脏脂肪以及血压。我们使用分段线性回归确定了25(OH)D与这些变量之间关联的阈值效应。我们发现25(OH)D与空腹血糖、空腹及餐后2小时胰岛素、HOMA-IR、腹部内脏脂肪、脂肪百分比、PTH及甘油三酯呈负相关。对于餐后2小时血糖、餐后2小时胰岛素、空腹胰岛素及HOMA-IR,发现了25(OH)D的阈值效应证据。没有证据表明需要种族特异性的正常25(OH)D浓度。IGF-1调节25(OH)D与结局之间的关系,但仅在25(OH)D浓度阈值以下,而非以上。我们的研究结果表明25(OH)D对葡萄糖-胰岛素代谢存在阈值效应,即25(OH)D≥约26μg/L(65.0pmol/L)有助于维持正常的葡萄糖稳态,并且定义正常25(OH)D浓度的相同切点可用于黑人和白人女性。本研究已在clinicaltrials.gov注册,注册号为NCT01798030。